What it is
Retatrutide acts on the GLP-1 and GIP receptors, like tirzepatide, and adds a third: the receptor for glucagon, a hormone that raises blood sugar. That third one is the big change. Acting on it can affect how much energy the body burns (energy expenditure) and how it uses fuels such as fat and sugar (substrate metabolism), on top of the appetite and blood-sugar effects of the other two.
What makes it distinct
Retatrutide is still in trials and isn't FDA-approved. Its doses come from those trials, not from a drug label.
How levels build
Open questions
- Whether acting on the glucagon receptor for a long time is safe in people.
- Its half-life (the time it takes for half a dose to clear) comes from a published study, not from an FDA label.
Worth knowing
No retatrutide product is FDA-approved, so there's no FDA label for it. Tidepath records what you tell it you're taking. It can't check what's in a vial.
Put your shot day in your calendar
A weekly reminder in the calendar you already use. It's made on your device; we never see your shot day.
More in The GLP-1 family